New hope for kids with rare immune disorder after other treatments fail
NCT ID NCT04943224
Summary
This study aims to find the safest and most effective way to use the drug trametinib for children with a rare immune system disorder called histiocytosis. It is for kids whose disease has not responded to standard treatments or a previous targeted drug, and who do not have a specific genetic marker (BRAF mutation). The trial will enroll about 12 young patients to carefully test different dosing schedules.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HISTIOCYTOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mother and Child Institute
RECRUITINGWarsaw, Mazovian, 01-211, Poland
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.